Latest Payments News

Page 9 of 644
Auric Mining has agreed to acquire the Iron Maiden Gold Project near Norseman for A$1 million upfront, while taking on project loans, deferred consideration and potential milestone payments. The shallow historical resource offers a new feed option for Burbanks, but it is not yet JORC 2012 compliant and the acquisition remains conditional.
Maxwell Dee
Maxwell Dee
10 Nov 2026
Evolution Mining has completed its acquisition of Carnaby Resources, becoming the registered holder of all Carnaby shares and issuing eligible holders 0.0682 Evolution shares for each Carnaby share. Carnaby is now moving to leave the ASX, with delisting expected after trading on 11 November.
Maxwell Dee
Maxwell Dee
10 Nov 2026
The Supreme Court of New South Wales has approved Arrovest’s proposed acquisition of Noumi, setting the transaction on course for a $0.1234-per-share payout. The schemes are not yet legally effective, with ASIC lodgement expected on 11 November and implementation targeted for 27 November.
Victor Sage
Victor Sage
10 Nov 2026
Lindian Resources has signed a binding term sheet covering 30,000 dry metric tonnes of Kangankunde monazite concentrate, with first shipments planned for January 2027. The unnamed refining group adds to Lindian’s growing customer base ahead of targeted December production, although the deal remains subject to full-form contracts, approvals and operational delivery.
Victor Sage
Victor Sage
10 Nov 2026
Nike is bringing Dan McKenzie back just months after his retirement to become chief accounting officer, ending CFO David Denton’s interim oversight of the function. The appointment comes with a US$500,000 salary, equity awards and a 12-month post-employment non-compete.
Victor Sage
Victor Sage
10 Nov 2026
Red Hill Minerals has granted Arrow Minerals a 12-month exclusive option to acquire its Pannawonica Iron Project, shifting holding costs and evaluation work to the potential buyer. If Arrow proceeds, Red Hill would receive $1 million plus uncapped royalties on future iron ore sales.
Maxwell Dee
Maxwell Dee
10 Nov 2026
EBR Systems delivered higher reimbursement, manufacturing and revenue milestones in the third quarter, but a sharp September slowdown and a formal going-concern warning have shifted attention to execution and funding. The company says it holds US$93.2 million in cash, cash equivalents and marketable securities, while US$41.8 million of debt falls due within 12 months.
Victor Sage
Victor Sage
10 Nov 2026
Novo Resources is using an A$37.69 million investment portfolio and about A$8.5 million in cash to fund a broad gold, copper and polymetallic exploration strategy. The opportunity is substantial, but so is the December A$10 million deferred payment and the need to convert conceptual targets into resources.
Maxwell Dee
Maxwell Dee
10 Nov 2026
OFX Group has swung from a A$2.4 million profit to a A$6.7 million statutory loss after weaker client activity and margin pressure cut first-half revenue. The company is betting that A$15 million in annualised cost reductions and modest revenue growth can restore profitability in the second half.
Claire Turing
Claire Turing
10 Nov 2026
Sheffield Resources has issued FY27 production guidance for its 50%-owned Thunderbird mine and modelled A$3.399 billion in life-of-mine free cash flow before debt and equity payments. The projections strengthen the case for a debt restructure, but remain dependent on operational improvements and lender approval of a proposed standstill.
Maxwell Dee
Maxwell Dee
10 Nov 2026
Akamai is seeking up to US$2.5 billion through convertible notes while temporarily loosening its leverage covenant and preparing for a US$1.15 billion debt maturity in 2027. The financing is also aimed at funding expansion of its Cloud Infrastructure Services business, but final pricing and potential dilution remain unresolved.
Sophie Babbage
Sophie Babbage
9 Nov 2026
Charles River Laboratories will pay about US$470 million in cash for Frontage’s bioanalysis and DMPK operations in Pennsylvania, with a further US$75 million tied to performance. The proposed acquisition expands Charles River’s clinical testing capabilities but will initially be neutral to non-GAAP earnings per share.
Ada Torres
Ada Torres
9 Nov 2026

Browse the archive

Full archive